<?xml version="1.0" encoding="UTF-8"?>
<p>There are several types of referrals in the European regulatory system. AMR-related concerns are mainly addressed under Article 30 and Article 31 of Directive 2001/83/EC [
 <xref rid="r8" ref-type="bibr">8</xref>]. These procedures may concern a specific medicinal product, a range of medicinal products (all containing the same active substance) or a therapeutic class of medicinal products and can be initiated by the EC, one of the EU Member States or the marketing authorisation holders of the concerned medicinal product. It can be triggered in the following specific cases: Article 30, when Member States adopt divergent decisions concerning the authorisation of medicinal products or to promote harmonisation of authorisations for medicinal products. The re-assessment of a medicinal product under Article 30 can be applied to a medicinal product that is approved for different indications in different Member States. Instead, an Article 31 referral can be triggered where the interest of the EU is involved. The term ‘interest of the Union’ refers particularly to the interests of public health related to medicinal products in the EU in light of quality, safety and efficacy data and related to the free movement of products within the EU [
 <xref rid="r9" ref-type="bibr">9</xref>].
</p>
